Missed GLP-1 Dose: Exactly What to Do, When to Skip, and How to Stay on Track

What Happens Biologically When You Miss a GLP-1 Dose

Missing a single injection does not erase weeks of progress, but it does shift your drug levels enough to affect appetite suppression and gastric emptying within days. Semaglutide has a mean half-life of approximately 165 hours, which means plasma concentrations drop by roughly half about one week after the last injection. Tirzepatide clears faster, with a half-life near 116 hours [1][2].

Because both drugs are dosed weekly, the therapeutic window is intentionally wide. A single missed dose rarely causes a full return of hunger signals in the first 48 to 72 hours. Beyond that window, however, patients frequently report renewed appetite, faster gastric emptying, and reduced satiety, all of which reflect the drug's waning receptor occupancy at GLP-1 (and, for tirzepatide, GIP) receptors in the hypothalamus and gut.

The Wegovy FDA prescribing label states directly: "If a dose is missed, administer as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day." [1] The 5-day rule in the label is measured from the scheduled injection day, not from when you noticed. Tirzepatide's Zepbound label uses the same 4-day window language, counting from the scheduled day [2].

The practical translation: if your scheduled day is Monday and it is now Wednesday evening, inject now. If it is Friday evening (4 or more days after Monday), skip it entirely and inject again next Monday.

The Complete GLP-1 Titration Schedule for Semaglutide and Tirzepatide

Titration exists to condition the gut and central nervous system before reaching a therapeutically effective dose. Jumping steps causes significantly higher rates of nausea, vomiting, and early discontinuation.

Wegovy (semaglutide 2.4 mg) titration:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Zepbound (tirzepatide 15 mg) titration:

• Weeks 1 to 4: 2.5 mg once weekly
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly
• Weeks 13 to 16: 10 mg once weekly
• Weeks 17 to 20: 12.5 mg once weekly
• Week 21 onward: 15 mg once weekly (maintenance)

In STEP-1 (N=1,961), 68 weeks of semaglutide 2.4 mg produced a mean weight loss of 14.9% versus 2.4% with placebo (P<0.001) [3]. SURMOUNT-1 (N=2,539) demonstrated even larger effects with tirzepatide 15 mg: 20.9% mean body weight reduction at 72 weeks versus 3.1% with placebo [4]. Both results assumed adherence to the full titration schedule.

What to do after missing doses during titration specifically: If you miss one dose, use the 48-hour catch-up rule above and continue on schedule. If you miss two consecutive doses at a titration step, stay at the current dose for an additional four weeks before advancing. If you miss two doses while recently having stepped up, step back to the previous dose for four weeks to minimize GI symptoms on re-escalation.

How to Handle a Missed Dose at Different Points in Therapy

The timing of the miss matters as much as the number of doses missed.

During the first 12 weeks (titration phase): Tolerance to GI side effects builds gradually at each step. Missing even one dose here means your gut has partially de-sensitized to the drug. When you resume, many patients experience renewed nausea at their previous dose level. Staying at the current dose for one extra week after a single miss is a clinically reasonable precaution, though the Wegovy label does not mandate it [1].

After reaching maximum tolerated dose (maintenance phase): A single missed dose is generally low-risk given the long half-life. Two consecutive missed doses at 2.4 mg semaglutide or 15 mg tirzepatide warrant a clinical discussion. Stepping back to 1.7 mg or 12.5 mg respectively for two to four weeks before returning to the full maintenance dose can reduce re-emergence of nausea.

After illness, travel, or a supply gap: Compounded semaglutide or tirzepatide supply interruptions are common. If the gap is three weeks or longer, treat the restart identically to starting from scratch on titration. The FDA notes that semaglutide reaches steady state after four to five weeks of weekly dosing [1], meaning a three-week gap effectively resets that steady state.

Weight Loss Plateaus on GLP-1 Therapy: Causes and Evidence-Based Responses

A plateau on GLP-1 therapy means losing less than 5% of body weight over 12 consecutive weeks while at maximum tolerated dose. Plateaus are common. They do not automatically mean the drug is failing.

STEP-5, the 104-week semaglutide extension trial, showed that patients who continued semaglutide 2.4 mg maintained an average 15.2% body weight loss at two years. Patients who completed the STEP-1 trial and then discontinued semaglutide regained two-thirds of their lost weight within one year [5]. This finding reframes the plateau: many patients who plateau at month 6 or 9 are simply approaching their new physiologic set point, not experiencing drug failure.

Reasons a plateau occurs on adequate GLP-1 dosing include:

1. Caloric compensation (increased food intake relative to energy expenditure as weight drops).
2. Reduced resting metabolic rate as lean mass is lost alongside fat mass.
3. Dose inadequacy because the patient never reached the highest tolerated step.
4. Non-adherence, including the irregular dosing patterns that lead to this article.

Practical responses to a plateau:

• Audit the actual injection log before changing any dose.
• If the patient has been steady at 1.7 mg semaglutide due to GI side effects, trialing a step to 2.4 mg with anti-nausea support (ondansetron 4 mg as needed) is reasonable.
• For tirzepatide, SURMOUNT-3 (N=579) showed that patients who completed a 12-week intensive lifestyle program before starting tirzepatide lost 24.5% body weight versus 15.7% in those who started tirzepatide without the lifestyle lead-in [6]. A structured behavioral intervention layered onto a plateau may restore momentum.
• If the patient is already at maximum tolerated dose and plateau persists beyond 16 weeks, a conversation about augmentation or alternative agents is appropriate.

The HealthRX clinical team uses a four-step plateau audit: (1) verify at least three months of weekly adherent dosing at maximum tolerated dose, (2) rule out thyroid dysfunction or cortisol excess with TSH and AM cortisol, (3) calculate actual dietary intake against estimated total daily energy expenditure using the Mifflin-St Jeor equation adjusted for activity, and (4) only after steps 1 through 3 are completed consider dose escalation or drug switch. Skipping to step 4 without the prior three steps is the most common provider-side error in plateau management.

Microdosing GLP-1 Medications: What It Means and Where the Evidence Stands

"Microdosing" in GLP-1 therapy refers to using doses below the approved titration schedule, typically 0.05 mg to 0.1 mg of semaglutide weekly, to test tolerance or manage side effects. No published randomized controlled trial has specifically evaluated a microdosing protocol for weight loss outcomes. Evidence here is limited to case series and clinical experience.

The rationale is physiologic. GLP-1 receptors in the area postrema (the brain's vomiting center) saturate at lower doses than receptors in the hypothalamus driving appetite suppression [7]. Starting extremely low may allow the gut to adapt before therapeutic concentrations are reached.

Where microdosing is used clinically:

• Patients with prior GI intolerance to standard titration who want to retry.
• Patients using compounded semaglutide, where dose flexibility exists beyond the fixed pen increments of the branded product.
• Patients with gastroparesis or inflammatory bowel disease where standard titration GI burden is unacceptable.

The FDA-approved prescribing information does not include a microdosing schedule [1]. Any protocol below 0.25 mg weekly is off-label. Patients should be counseled that sub-therapeutic doses may slow weight loss results and that adherence to the labeled titration, when tolerated, produces the outcomes documented in the large RCTs.

One critical note on compounded products: the FDA has issued several alerts about dosing errors with compounded semaglutide, particularly because base-unit milligram quantities on compounding pharmacy labels sometimes require patients to calculate their own volumes. A dose of 0.25 mg in a standard pharmacy product is straightforward. The same dose from a 5 mg/mL compounded vial requires drawing 0.05 mL, a measurement that produces significant error with insulin syringes [8].

Maintenance Dose: What It Is and How Long You Stay on It

The maintenance dose is not a finish line. It is the dose at which a patient's weight loss has plateaued at an acceptable level and ongoing medication use sustains that loss.

For semaglutide, the labeled maintenance dose is 2.4 mg weekly (Wegovy) or 1.0 to 2.0 mg weekly (Ozempic for type 2 diabetes) [1]. For tirzepatide, the Zepbound label describes 5 mg, 10 mg, or 15 mg as maintenance doses, with 15 mg producing the greatest weight reduction in SURMOUNT-1 [2][4].

Not every patient reaches the maximum dose. SURMOUNT-4 (N=670) tested what happens when tirzepatide is withdrawn after 36 weeks of active treatment. Patients on placebo after withdrawal regained 14.8% of body weight over 52 weeks, while those who continued tirzepatide lost an additional 5.5% [9]. This is the clearest available evidence that GLP-1 and dual GIP/GLP-1 agonists function as ongoing metabolic management, not a course of treatment with a defined end date.

The 2016 AACE/ACE obesity clinical practice guidelines, which predate GLP-1 approvals for obesity but remain foundational, state: "Anti-obesity medications approved as an adjunct to lifestyle therapy are indicated for patients with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity, and should be continued long-term if the patient responds and tolerates the medication." [10] This framing applies directly to current GLP-1 agents.

How to know if you can step down from maintenance dose:

A step-down from 2.4 mg to 1.7 mg semaglutide (or from 15 mg to 10 mg tirzepatide) may be appropriate when:

• Body weight has been stable for six months at goal.
• GI side effects remain bothersome at the higher dose.
• The patient and provider agree that a lower dose with monthly weight monitoring is acceptable, understanding that weight regain is possible.

The SELECT cardiovascular outcomes trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 34 months in patients with pre-existing cardiovascular disease and overweight or obesity [11]. This cardiometabolic benefit is an additional argument for long-term continuation in high-risk patients, independent of the weight loss outcome.

Injection Site, Day Consistency, and Practical Adherence Tips

Consistent day-of-week dosing is not arbitrary. Because GLP-1 agents take approximately 24 to 72 hours to reach peak plasma concentration after subcutaneous injection, injecting on the same day each week maintains a stable trough-to-peak ratio. Rotating days shifts that ratio unpredictably.

Approved injection sites are the abdomen (at least 2 inches from the navel), the anterior thigh, and the upper arm. Rotating sites within these regions prevents lipodystrophy. The abdomen generally produces the fastest absorption; the thigh the slowest, though clinically the difference is small for a once-weekly drug.

In STEP-8 (N=338), a head-to-head comparison of semaglutide 2.4 mg versus liraglutide 3 mg over 68 weeks, semaglutide produced 15.8% weight loss versus 6.4% for liraglutide (P<0.001) [12]. The superiority was partly attributed to semaglutide's longer half-life and more stable weekly dosing profile compared to liraglutide's daily injection requirement, which carries a higher missed-dose burden.

Four practical steps to reduce missed doses:

1. Pair the injection with a fixed weekly event: Sunday dinner prep, a specific TV program, or a standing calendar alert.
2. Store pens at the front of the refrigerator, not behind other items.
3. Use the 48-hour catch-up rule and set a backup reminder 48 hours after your primary reminder, labeled "last chance window."
4. If travel crosses time zones, keep the day consistent by local time at your destination, not by your home time zone.

When to Call Your Provider Instead of Self-Managing a Missed Dose

Most single missed doses are self-manageable with the rules above. Call your provider or telehealth team when:

• You have missed three or more consecutive doses and are unsure how far to step back.
• You are experiencing persistent nausea, vomiting, or severe abdominal pain after resuming a dose, which may indicate pancreatitis and requires immediate evaluation.
• You are taking insulin or a sulfonylurea alongside semaglutide or tirzepatide, because dose interruptions can shift blood glucose unpredictably.
• Your weight has increased by more than 5% since your last measured weight despite reported adherence, which suggests either absorption issues or an undisclosed adherence gap.

The STEP-2 trial (N=1,210), which studied semaglutide 1.0 mg and 2.4 mg in patients with type 2 diabetes, documented that HbA1c reduction was tightly correlated with dose consistency [13]. Even in non-diabetic patients, the metabolic consistency argument holds: irregular dosing produces irregular outcomes.